Fenia Theodorakakou

[JohnNtan @johnntanasis]

Late-breaking SUCCESSOR-2 results presented by @thanosdimop @UoATherapeutics #EHA2026
https://t.co/o5S1Y04Dll

[Θερ��πευτική Κλινική ΕΚΠΑ / NKUA Therapeutics @UoATherapeutics]

Η Αιματολογική και Ογκολογική Μονάδα της Θεραπευτικής Κλινικής ΕΚΠΑ, με έδρα το Γενικό Νοσοκομείο Αλεξάνδρα, κατά τη διάρκεια του 2025, κατέγραψε ισχυρή παρουσία στην παγκόσμια επιστημονική κοινότητα!

@thanosdimop

https://t.co/K27rWaQDeC

https://t.co/OV1Jh7reeQ

[JohnNtan @johnntanasis]

Denosumab in RI by Prof Terpos and Validation of CGS high risk criteria by Prof Kastritis at #ASH2025 in Orlando @StathisKastr @thanosdimop @mgavriatopoulou @UoATherapeutics #mmsm

[JohnNtan @johnntanasis]

Long-term results from the prospective MRD-driven lenalidomide discontinuation trial presented by @panmalandrakis at #ESMO25 in #Berlin #mmsm @UoATherapeutics @thanosdimop @mgavriatopoulou

[JohnNtan @johnntanasis]

@panmalandrakis received the young investigator award at the International Myeloma Workshop 2025 in Toronto ! @UoATherapeutics @thanosdimop @mgavriatopoulou #IMS2025

[Thanos Dimopoulos @thanosdimop]

Drs Dispenzieri and Kastritis at the meet the expert session on amyloidosis at IMS 2025

[Thanos Dimopoulos @thanosdimop]

Myeloma can be cured in some patients and these numbers will increase with current therapist https://t.co/tlVOKaBxit

[Thanos Dimopoulos @thanosdimop]

Just published! Updated EHA-EMN guidelines for the diagnosis, treatment and follow-up of #MultipleMyeloma! #mmsm https://t.co/Xfg7vrAcTH
@EHA_Hematology @EMN_EuMMnet @UoATherapeutics

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: Revised renal stratification & progression model w/ 4-stages predicts long-term AL #amyloidosis outcomes; risk of PD to renal replacement increased in stages (Hazard ratio: 3.25, 5.13, 10.66 for Stages 2A, 2B & 3 vs. 1): https://t.co/Ozf0Qe15zo. #mmsm

[Vincent Rajkumar @VincentRK]

Key Myeloma therapy update for 2025

1) Newly diagnosed: Start treatment with quads, if possible. (Dara-VRd or Isa-VRd).

2) Auto Transplant: can be deferred for standard risk patients, especially if good response to induction. But collect and store stem cells for future use.

3) Maintenance: Doublet maintenance with Dara/ Len or bortezomib/ Len for high risk myeloma. Either Single or Doublet maintenance for standard risk.

4) Use new IMWG IMS risk stratification

5) First relapse: standard triplet therapy is fine for most. CART in first relapse mainly for functional high risk (progression or early relapse with induction).

6) When using CART, disease burden should be controlled and minimal to reduce risk of serious toxicity.

[Irene Solia @eirsolia]

Prof @thanosdimop presented at #EHA2025 in Milan, the initial results from MagnetisMM-6 trial
@UoATherapeutics

[Victor H Jimenez-Zepeda @vhugo8762]

Sparing dexamethasone strategies for TI MM! #EHA2025

[JohnNtan @johnntanasis]

Dr Maria Gavriatopoulou @mgavriatopoulou co-chairs with Dr Mattia D'Agostino @Dagostino_MD the session on Novel Prognostic Features in Plasma Cell Disorders #EHA2025 @UoATherapeutics

[Vincent Rajkumar @VincentRK]

Just out: Mayo Clinic mSMART Risk Stratification of Myeloma
#EHA25

1/ We recommend and use same high risk cytogenetic definition as the latest IMS/IMWG paper

2/ Primary plasma cell leukemia is high risk myeloma

3/ We define Double-hit high risk myeloma

https://t.co/R4hz7umwEJ

[JohnNtan @johnntanasis]

Prof Terpos and Gavriatopoulou @mgavriatopoulou present the updated 2025 EHA-EMN Clinical Practice Guidelines for Multiple Myeloma Diagnosis, Treatment and Follow-up at the #EHA2025 #EHA in Milan !
@UoATherapeutics @thanosdimop

[Vaishali Sanchorawala @vsanchorawala]

Not all advances meet our hopes. Birtamimab, an anti-amyloid fibril agent, did not improve survival in the AFFIRM-AL trial for Mayo Stage IV AL amyloidosis. A disappointing result—but a clear reminder of the need for continued progress. @BU_Amyloidosis

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

Now in @BloodJournal: congrats @thanosdimop et al on studying this prospectively!

I love the abstract! Stopping len is a burning question for the #MMsm community and can also stop burning holes in our pocketbooks 💸

Good to see such great post-discontinuation PFS data here!

[Muzaffar Qazilbash @Transplant_Doc]

Discontinuation of Len maint. 3 years post autoHCT with sustained BM and imaging MRD -ve status. N=52, 7-year PFS: 90%, 3-year treatment-free survival: 75.8% #mmsm #btsm @thanosdimop @BloodJournal https://t.co/lP9FOQb9Pl

[Carol Whelan @CJWhelan18]

Melbourne in May on Amyloidosis Day! Great workshop with @StathisKastr
The @OzAmyloidosis patients’ association is now led by Maureen & Garry Mahon (took over from the great Pat Neely). Loved catching up with Brendan, Olga and James. Thank you.

[Θεραπευτική Κλινική ΕΚΠΑ / NKUA Therapeutics @UoATherapeutics]

Νέα δημοσίευση για το Πολλαπλό Μυέλωμα στο κορυφαίο επιστημονικό περιοδικό New England Journal of Medicine με πρώτο συγγραφέα τον Διευθυντή της Θεραπευτικής Κλινικής ΕΚΠΑ Καθηγητή Θάνο Δημόπουλο! @thanosdimop